Medicure (MPH) AI Stock Analysis

• Market Cap: C$13.05M
• Dividend Yield: N/A
• Average Volume (3M): 1.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: -0.29%
• EPS Growth: -53.83%
• Country: CA
• Employees: 25
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 10,436,313
• 10 Day Avg. Volume: 1,510
• 30 Day Avg. Volume: 1,056
• PEG Ratio: -0.03
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: C$1.00 ▼(-20.00%Downside)

The overall stock score is primarily influenced by the company's challenging financial performance and poor valuation metrics. While technical indicators suggest positive momentum, the lack of profitability and negative earnings significantly impact the overall attractiveness of the stock.

Medicure Business Overview & Revenue Model

Company Description

Medicure (MPH) is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of cardiovascular diseases. The company operates in the healthcare sector, with a particular emphasis on prescription drugs and medical products. Its core offerings include the production and distribution of branded pharmaceuticals, primarily targeting conditions such as hypertension and heart failure.

How the Company Makes Money

Medicure makes money through the sale of its pharmaceutical products, which are marketed directly to healthcare providers and institutions. The company's revenue is primarily generated from its flagship cardiovascular drug, which is distributed across various markets. Additionally, Medicure earns income through strategic partnerships and licensing agreements with other pharmaceutical firms, which may involve co-development or co-promotion of products. These collaborations can provide upfront payments, milestone payments, and royalties based on product sales. The company also invests in research and development to expand its product pipeline, aiming to introduce new treatments to the market, thereby increasing its potential revenue streams.

Medicure Financial Statement Overview

Summary

Medicure demonstrates potential in revenue growth and a strong equity base, but faces significant challenges with profitability and cash flow consistency. The negative EBIT and net profit margins coupled with volatile free cash flow indicate operational inefficiencies.

Income Statement

Medicure has shown some improvement in revenue over the years, but profitability remains a concern with recurring net losses. The gross profit margin is relatively stable, but negative EBIT and net profit margins indicate operational challenges. The revenue growth is slow, and efforts to improve EBITDA have not fully translated into net profitability.

Balance Sheet

The company's balance sheet shows moderate financial stability with a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio suggests that a good portion of the assets is funded by equity, which is a positive sign of financial health.

Cash Flow

Medicure's cash flow from operations is positive, but free cash flow has been inconsistent due to capital expenditures. The operating cash flow to net income ratio is favorable, indicating strong cash generation relative to earnings. However, the free cash flow growth rate is volatile, reflecting fluctuations in investment and capital spending.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.91M	21.69M	23.07M	21.74M	11.61M
Gross Profit	13.09M	13.99M	16.07M	12.71M	5.13M
EBITDA	1.53M	1.27M	3.44M	2.39M	-4.04M
Net Income	-1.04M	-922.00K	1.36M	-727.00K	-6.84M
Balance Sheet
Total Assets	29.68M	28.06M	29.90M	28.41M	34.05M
Cash, Cash Equivalents and Short-Term Investments	7.19M	6.37M	4.86M	3.69M	2.72M
Total Debt	874.00K	544.00K	849.00K	1.17M	1.45M
Total Liabilities	8.90M	8.16M	8.89M	10.00M	14.91M
Stockholders Equity	20.78M	19.90M	21.00M	18.41M	19.15M
Cash Flow
Free Cash Flow	638.00K	1.81M	1.52M	3.17M	-2.24M
Operating Cash Flow	1.38M	2.08M	1.83M	3.99M	-2.24M
Investing Cash Flow	-739.00K	-270.00K	-310.00K	-2.69M	-7.24M
Financing Cash Flow	-370.00K	-297.00K	-355.00K	-316.00K	-766.00K

Medicure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MPH, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.00, and above the 200-day MA of 0.92, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 64.91 is Neutral, neither overbought nor oversold. The STOCH value of 78.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MPH.

Medicure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDP	71 Outperform	C$101.61M	24.53	5.27%	―	-3.82%	-50.36%
CTX	54 Neutral	C$9.37M	―	-18.52%	―	1.14%	-36.66%
MPH	52 Neutral	C$13.05M	―	-8.79%	―	-0.29%	-53.83%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
TH	49 Neutral	$150.81M	―		―	16.23%	85.76%
RVV	46 Neutral	C$8.37M	―	-50.76%	―	―	-4.84%
MVMD	35 Underperform	C$7.05M	―	-44.58%	―	-48.33%	47.56%

Medicure Corporate Events

Medicure Completes Acquisition of West Olympia Pharmacy

Medicure Inc. has completed the acquisition of West Olympia Pharmacy, aligning with its strategic plan to expand its direct-to-consumer pharmacy business. This acquisition, along with the previous acquisition of Gateway Medical Pharmacy, is expected to add approximately $10 million in additional annual net revenue, enhancing the company’s pharmacy business and strengthening sales of its marketed products.

Medicure Inc. Reports 2024 Financial Results with Increased Revenue but Net Loss

Medicure Inc. reported its financial results for the year ended December 31, 2024, with total net revenue of $21.9 million, a slight increase from the previous year. Despite increased revenue from Marley Drug and ZYPITAMAG sales, the company faced a net loss of $1.0 million, primarily due to decreased AGGRASTAT sales and increased costs. The results reflect challenges from pricing competition and increased operational expenses, impacting the company’s profitability.

Medicure to Announce 2024 Financial Results

Medicure Inc. announced it will present its 2024 Year End Financial Results via a conference call on April 29, 2025. The financial results will be filed after market close on April 28, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, which could impact its industry positioning and future strategies.

Medicure Expands U.S. Pharmacy Business with West Olympia Acquisition

Medicure Inc. announced the acquisition of West Olympia Pharmacy, expanding its direct-to-consumer pharmacy business in the United States. This acquisition aligns with Medicure’s strategic plan to enhance its pharmacy operations, leveraging West Olympia’s customer base to accelerate the growth of its product ZYPITAMAG and other services. The transaction, valued at USD $975,000, will be funded using existing cash without incurring debt, and is expected to facilitate better access and cost efficiency for patients.